A randomized, double-blind, placebo-controlled, dose escalation study of multiple oral dose administration of BIIB014 [V-2006] in subjects with early Parkinson's disease.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2015
At a glance
- Drugs Vipadenant (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Biogen
- 25 May 2007 New trial record.